Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy

摘要: Lung cancer is one of the leading causes death with lowest survival rates. However, a subset lung patients who are Asian origin and carry somatic mutations in epidermal growth factor receptor or EGFR have responded remarkable well to two tyrosine kinase inhibitors, gefitinib erlotinib. While mutation profiles been reported from Japan, South Korea, Taiwan, there no such report mainland China where largest pool reside. In this report, we identified ten total 41 China. Among them, seven were found 17 adenocarcinomas. contrast previous reports, eight these deletions exon 19 homozygous. These results suggest that large portion Chinese adenocarcinoma could benefit This unique profile provides rationale develop next generation inhibitors more suitable for population.